Why Jardiance is Prescribed for Heart Failure Patients
Jardiance (empagliflozin) is prescribed for heart failure patients because it significantly reduces the risk of cardiovascular death and hospitalization for heart failure by approximately 25%, regardless of whether the patient has diabetes. This benefit has been consistently demonstrated across the entire spectrum of heart failure, from reduced to preserved ejection fraction.
Evidence-Based Benefits
For Heart Failure with Reduced Ejection Fraction (HFrEF)
In the EMPEROR-Reduced trial, empagliflozin 10 mg daily reduced the composite endpoint of cardiovascular death or heart failure hospitalization by 25% (HR 0.75; 95% CI 0.65-0.86) in patients with LVEF ≤40% 1. The benefit was driven primarily by a 31% reduction in heart failure hospitalizations 2. Importantly, this benefit occurred equally in patients with and without type 2 diabetes 3.
For Heart Failure with Preserved Ejection Fraction (HFpEF)
The EMPEROR-Preserved trial demonstrated that empagliflozin reduced the primary composite outcome by 21% (HR 0.79; 95% CI 0.69-0.90) in patients with LVEF >40% 4, 5. Again, the effects were consistent regardless of diabetes status 6.
Mechanism of Action in Heart Failure
While Jardiance was originally developed as a diabetes medication that works by blocking glucose reabsorption in the kidneys, its heart failure benefits extend far beyond glucose lowering 2, 7. The cardioprotective mechanisms include:
- Hemodynamic improvements: Reduces preload through osmotic diuresis and decreases afterload
- Cardiac remodeling: Empagliflozin reduced left ventricular end-systolic volume by 6.0 mL/m² and end-diastolic volume by 8.2 mL/m² 8, 9
- Improved myocardial energetics: Enhances mitochondrial function and substrate flexibility 7
- Renal protection: Reduces kidney injury markers and slows eGFR decline 10
Clinical Application Algorithm
When to prescribe Jardiance for heart failure:
HFrEF (LVEF ≤40%): Start empagliflozin 10 mg daily as part of guideline-directed medical therapy, regardless of diabetes status 11, 2
HFpEF (LVEF >40%): Start empagliflozin 10 mg daily in symptomatic patients (NYHA class II-IV) 3, 2
Diabetes + Heart Failure: Empagliflozin is strongly recommended to reduce heart failure hospitalization and cardiovascular death 12, 13
Key prescribing considerations:
- eGFR threshold: Can be initiated down to eGFR 20 mL/min/1.73 m² (EMPEROR-Reduced excluded <20; DAPA-HF excluded <30) 11, 1
- Timing: Start early in disease course alongside other guideline-directed therapies; do not wait for optimization of other medications 11
- Dosing: 10 mg once daily (the dose used in heart failure trials) 1
Safety Profile
The medication is generally well-tolerated with specific monitoring needed for:
- Genital mycotic infections (10-15% in women, higher in uncircumcised men) - typically manageable with antifungals without discontinuation 11
- Volume depletion - may require diuretic adjustment 2
- Temporary eGFR decrease (up to 15%) - usually resolves within 1-3 months and represents hemodynamic effect, not kidney injury 11
- Euglycemic ketoacidosis - rare but requires awareness, especially during sick days 11, 2
Magnitude of Benefit
The number needed to treat is 35 over 3 years to prevent one heart failure hospitalization or cardiovascular death 14. This represents one of the most significant advances in heart failure therapy in recent years, with benefits seen across:
- First and recurrent heart failure hospitalizations (30% reduction) 2, 1
- Cardiovascular death (18% reduction with dapagliflozin) 3
- All-cause mortality (17% reduction) 2
- Quality of life improvements 13, 15
The 2024 ADA Standards of Care, 2022 ACC/AHA/HFSA Heart Failure Guidelines, and 2021 Canadian Heart Failure Guidelines all give Strong Recommendations with High-Quality Evidence for SGLT2 inhibitors in heart failure 3, 11, 2. This represents a paradigm shift where a "diabetes drug" has become foundational therapy for all heart failure patients, with or without diabetes.